Protagonist Therapeutics, Inc (PTGX) stock
PTGXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 6, 2026Score 12/30195% above fair value
$121.40−2.62 (-2.11%)
Close on Nov 20, 2026Market cap $7.86BP/E 117.9Yield –
Protagonist Therapeutics free cash flow
Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.
Protagonist Therapeutics's free cash flow for the twelve months ending Jun 30, 2026 was $130.58M, up 252.0% year over year. For fiscal 2025 it was $56.08M, down 69.3% from the year before. The highest annual figure on record is $182.80M in fiscal 2024.
Annual free cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $56.08M | -69.3% |
| FY2024 | Dec 31, 2024 | $182.80M | – |
| FY2023 | Dec 31, 2023 | -$70.85M | – |
| FY2022 | Dec 31, 2022 | -$108.93M | – |
| FY2021 | Dec 31, 2021 | -$108.97M | – |
| FY2020 | Dec 31, 2020 | -$72.96M | – |
| FY2019 | Dec 31, 2019 | -$42.49M | – |
| FY2018 | Dec 31, 2018 | -$50.43M | -1673.1% |
| FY2017 | Dec 31, 2017 | $3.21M | – |
| FY2016 | Dec 31, 2016 | -$30.32M | – |
| FY2015 | Dec 31, 2015 | -$14.78M | – |
| FY2014 | Dec 31, 2014 | -$8.04M | – |
Quarterly free cash flow
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $218.88M | – |
| Q1 FY2026 | Mar 31, 2026 | -$49.16M | -139.4% |
| Q4 FY2025 | Dec 31, 2025 | -$37.12M | – |
| Q3 FY2025 | Sep 30, 2025 | -$2.03M | – |
| Q2 FY2025 | Jun 30, 2025 | -$29.59M | -111.0% |
| Q1 FY2025 | Mar 31, 2025 | $124.82M | – |
| Q4 FY2024 | Dec 31, 2024 | -$29.49M | -274.1% |
| Q3 FY2024 | Sep 30, 2024 | -$28.64M | – |
| Q2 FY2024 | Jun 30, 2024 | $268.59M | – |
| Q1 FY2024 | Mar 31, 2024 | -$27.67M | – |
| Q4 FY2023 | Dec 31, 2023 | $16.94M | – |
| Q3 FY2023 | Sep 30, 2023 | -$27.02M | – |
| Q2 FY2023 | Jun 30, 2023 | -$26.41M | – |
| Q1 FY2023 | Mar 31, 2023 | -$34.36M | – |
| Q4 FY2022 | Dec 31, 2022 | -$31.71M | – |
| Q3 FY2022 | Sep 30, 2022 | -$25.36M | – |
| Q2 FY2022 | Jun 30, 2022 | -$13.93M | – |
| Q1 FY2022 | Mar 31, 2022 | -$37.94M | – |
| Q4 FY2021 | Dec 31, 2021 | -$27.14M | – |
| Q3 FY2021 | Sep 30, 2021 | -$28.74M | – |
| Q2 FY2021 | Jun 30, 2021 | -$24.20M | – |
| Q1 FY2021 | Mar 31, 2021 | -$28.90M | – |
| Q4 FY2020 | Dec 31, 2020 | -$18.99M | – |
| Q3 FY2020 | Sep 30, 2020 | -$16.36M | – |
| Q2 FY2020 | Jun 30, 2020 | -$21.62M | -878.1% |
| Q1 FY2020 | Mar 31, 2020 | -$15.99M | – |
| Q4 FY2019 | Dec 31, 2019 | -$14.51M | – |
| Q3 FY2019 | Sep 30, 2019 | -$13.94M | – |
| Q2 FY2019 | Jun 30, 2019 | $2.78M | – |
| Q1 FY2019 | Mar 31, 2019 | -$16.83M | – |
| Q4 FY2018 | Dec 31, 2018 | -$10.20M | – |
| Q3 FY2018 | Sep 30, 2018 | -$9.42M | -123.3% |
| Q2 FY2018 | Jun 30, 2018 | -$15.47M | – |
| Q1 FY2018 | Mar 31, 2018 | -$15.35M | – |
| Q4 FY2017 | Dec 31, 2017 | -$14.21M | – |
| Q3 FY2017 | Sep 30, 2017 | $40.51M | – |
| Q2 FY2017 | Jun 30, 2017 | -$12.70M | – |
| Q1 FY2017 | Mar 31, 2017 | -$10.40M | – |
| Q4 FY2016 | Dec 31, 2016 | -$9.73M | – |
| Q3 FY2016 | Sep 30, 2016 | -$7.00M | – |
See a number that looks wrong?